Offrimed
Developer of human digital twin technology that creates statistically matched virtual patients from multi‑modal biomedical and clinical data to support clinical trial design, predictive simulation, hybrid control arms, and preclinical in‑silico prediction. Provides platform and project services for trial simulation, real‑time analytics, cohort construction, and in‑silico drug/target prediction intended to reduce trial size, time, and costs and to provide alternatives or supplements to animal testing.
Industries
Nr. of Employees
small (1-50)
Offrimed
Headquarters: Room 601, Ulsan Startup Hub, Jongha Innovation Center, 32 Bongwol-ro 38beon-gil, Nam-gu, Ulsan, South Korea; Big Data Lab: 10F Room 1001, Gwanggyo Central Business Tower, 260 Changnyong-daero, Yeongtong-gu, Suwon, Gyeonggi Province
Products
Human digital twin platform
Platform that creates statistically matched virtual patients for clinical simulation, cohort generation, and outcome prediction.
Virtual-patient management and real-time simulation platform
Platformized access to virtual cohorts with real‑time simulation and analytics for protocol design and operational forecasting.
Trial analytics and outcome prediction suite
Toolset for predicting trial duration, dropout and adverse event rates, approval probabilities, dose optimization, and root‑cause analysis of trial failures.
Human digital twin platform
Platform that creates statistically matched virtual patients for clinical simulation, cohort generation, and outcome prediction.
Virtual-patient management and real-time simulation platform
Platformized access to virtual cohorts with real‑time simulation and analytics for protocol design and operational forecasting.
Trial analytics and outcome prediction suite
Toolset for predicting trial duration, dropout and adverse event rates, approval probabilities, dose optimization, and root‑cause analysis of trial failures.
Services
Provision of virtual patient cohorts and management tools to support simulation, synthetic control construction, and cohort lifecycle management.
Design and simulation services for hybrid trials that combine real and virtual participants, including endpoint prediction, sample size optimization, and trial analytics.
Project‑based modeling services that predict preclinical outcomes (toxicity, PK/PD) from animal and experimental datasets to inform study design and reduce animal use.
Operational analytics during active studies including enrollment forecasting, dropout and adverse event prediction, interim outcome assessment, and risk identification.
Provision of virtual patient cohorts and management tools to support simulation, synthetic control construction, and cohort lifecycle management.
Design and simulation services for hybrid trials that combine real and virtual participants, including endpoint prediction, sample size optimization, and trial analytics.
Project‑based modeling services that predict preclinical outcomes (toxicity, PK/PD) from animal and experimental datasets to inform study design and reduce animal use.
Operational analytics during active studies including enrollment forecasting, dropout and adverse event prediction, interim outcome assessment, and risk identification.
Expertise Areas
- Human digital twin modelling for clinical research
- Clinical trial simulation and design optimization
- Hybrid trial and synthetic/external control-arm methodologies
- Predictive analytics and machine learning for clinical outcomes
Key Technologies
- Human digital twin modelling
- Virtual patient generation
- Machine learning and deep learning
- Multi‑modal data ingestion (EHR/EMR, imaging, genomics, biosignals)
News & Updates
Article describing the company's digital twin platform and the application of virtual patients for clinical trial design and population‑specific simulation.
Selected for the Korean Deep Tech TIPS program with funding support to advance the digital twin technology and accelerate global expansion (reported support up to KRW 1.5–1.7 billion).
CEO received the Chairperson’s Award from the Korea Center for Women in Business in recognition of work in AI and bio‑health technology.
Article describing the company's digital twin platform and the application of virtual patients for clinical trial design and population‑specific simulation.
Selected for the Korean Deep Tech TIPS program with funding support to advance the digital twin technology and accelerate global expansion (reported support up to KRW 1.5–1.7 billion).
CEO received the Chairperson’s Award from the Korea Center for Women in Business in recognition of work in AI and bio‑health technology.